Literature DB >> 16766593

A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy.

T R Halfdanarson, S N Markovic, U Kalokhe, M Luppi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766593     DOI: 10.1093/annonc/mdl139

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  21 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

Review 2.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

3.  Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient.

Authors:  Rui Pereira; Joana Carvalho; Catarina Patrício; Pedro Farinha
Journal:  BMJ Case Rep       Date:  2014-10-13

Review 4.  Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.

Authors:  Tamara K Moyo; Kristy L Richards; Blossom Damania
Journal:  Clin Adv Hematol Oncol       Date:  2010-05

5.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012

6.  STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Christine A King; Xiaofan Li; Arturo Barbachano-Guerrero; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

7.  Primary effusion lymphoma diagnosed by pericardiocentesis.

Authors:  Michael C Nemunaitis; Jeffrey M Schussler; S Michelle Shiller; Louis M Sloan; Robert G Mennel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-01

8.  Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.

Authors:  Arun George Paul; Neelam Sharma-Walia; Bala Chandran
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

9.  β-HHVs and HHV-8 in Lymphoproliferative Disorders.

Authors:  C Quadrelli; P Barozzi; G Riva; D Vallerini; E Zanetti; L Potenza; F Forghieri; M Luppi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

10.  An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV-positive, cirrhotic patient, and review of the literature.

Authors:  Charitini Nepka; Dimitrios Kanakis; Maria Samara; Andreas Kapsoritakis; Spyridon Potamianos; Maria Karantana; Georgios Koukoulis
Journal:  Cytojournal       Date:  2012-06-29       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.